TP53 mutation drives cancer IR-resistance via the Arf6-based pathway

2016 Fiscal Year Final Research Report

• Project/Area Number: 26293057
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: General medical chemistry
• Research Institution: Hokkaido University
• Principal Investigator: Sabe Hisataka 北海道大学, 医学(系)研究科(研究院), 教授 (40187282)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 放射線抵抗性 / Arf6 / TP53

Outline of Final Research Achievements

Ionizing radiation (IR) is amongest a promissing method of the cancer therapeutics. We have shown previous that the small-GTPase Arf6 and its downstream signaling factors are frequently overexpressed in different cancers and execute a cancer mesenchymal program, including invasion and metastasis. We have furthermore identified that this pathway is a core to promote IR-resistance of cancer cells. Here, we show a precise mechanism by which the Arf6-based pathway contributes to the cancer IR-resistance, and identified a critical gene mutation therein involved.

Free Research Field

分子腫瘍学